Analysis of the Efficiency of Gene-Cell Therapy in Transgenic Mice with Amyotrophic Lateral Sclerosis Phenotype

Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by progressive death of cerebral and spinal motorneurons. Using behavioral tests we studied the efficiency of gene-cell therapy in SOD1 G93A transgenic mice receiving xenotransplantation of human umbilical cord blood mononucl...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2013-02, Vol.154 (4), p.558-561
Main Authors: Mukhamedyarov, M. A., Rizvanov, A. A., Safiullov, Z. Z., Izmailov, A. A., Sharifullina, G. A., Solovieva, V. V., Fedotova, V. Yu, Salafutdinov, I. I., Cherenkova, E. E., Bashirov, F. V., Kaligin, M. S., Abdulkhakov, S. R., Shmarov, M. M., Logunov, D. Yu, Naroditsky, B. S., Kiyasov, A. P., Zefirov, A. L., Islamov, R. R.
Format: Article
Language:English
Subjects:
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - physiopathology
Amyotrophic Lateral Sclerosis - therapy
Animals
Biomedical and Life Sciences
Biomedicine
Cell Biology
Cell- and Tissue-Based Therapy - methods
Fluorescence
Gene therapy
Genes
Genetic aspects
Genetic engineering
Genetic Therapy - methods
Genetically modified organisms
Humans
Internal Medicine
Laboratory Medicine
Mice
Mice, Transgenic
Nervous system diseases
Pathology
Superoxide Dismutase - genetics
Superoxide Dismutase - metabolism
Transplantation, Heterologous
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - genetics
Vascular Endothelial Growth Factor A - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by progressive death of cerebral and spinal motorneurons. Using behavioral tests we studied the efficiency of gene-cell therapy in SOD1 G93A transgenic mice receiving xenotransplantation of human umbilical cord blood mononuclear cells genetically modified with adenoviral vectors encoding vascular endothelial growth factor (VEGF) and reporter green fluorescent protein (EGFP) genes. The cells were transplanted to mice on week 27 of life (preclinical stage of the disease). Behavioral tests (open field, grip strength test) showed that transplantation of umbilical cord blood mononuclear cells expressing VEGF significantly improved the parameters of motor and explorative activity, grip strength, and animal survival. Thus, gene-cell therapy based on genetically modified mononuclear cells expressing VEGF can be efficient for the treatment of amyotrophic lateral sclerosis.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-013-1999-2